Royalty Pharma plc Business Operations Contracts & Agreements
19 Contracts & Agreements
- Development Agreements (10 contracts)
- Management Agreements (9)
- Second Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on November 8, 2022)
- Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Holdings Limited and RP Management, LLC (Filed With SEC on November 8, 2022)
- Amended and Restated Management and Services Agreement dated October 3, 2022, among the Company and RP Management, LLC (Filed With SEC on November 8, 2022)
- Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on October 13, 2020)
- Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis... (Filed With SEC on October 13, 2020)
- Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)
- Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)
- Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)
- Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as... (Filed With SEC on October 13, 2020)
- Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC (Filed With SEC on October 13, 2020)
- Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on June 19, 2020)
- Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC (Filed With SEC on June 19, 2020)
- Form of Amended and Restated Management and Services Agreement, dated, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on May 22, 2020)
- Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis... (Filed With SEC on May 22, 2020)
- Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)
- Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)
- Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)
- Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as... (Filed With SEC on May 22, 2020)
- Form of Management and Services Agreement, dated , 2020, among Royalty Pharma plc and RP Management, LLC (Filed With SEC on May 22, 2020)
